Real-time financial
intelligence.
Signal, not noise.
Real-time signals from 100+ primary-source feeds — AI-summarized, analyst-supervised, on your screen seconds after the issuer presses send.
14-day free trial · $0 today · Cancel anytime before charge
Real-time wires
Adaptive cadence — 5s pre-market and after-hours, 15s during the regular session. Direct from issuer wires, no aggregator delay.
AI, analyst-supervised
Every release distilled by a frontier model and validated against rules from a working market analyst. Schema-checked before publish.
Coverage breadth
PR Newswire, GlobeNewswire, BusinessWire, EDGAR 8-Ks, Newsfile, Accesswire, gov releases (FDA, FTC, DOJ), and 60+ more.
Catalysts in context
Earnings with consensus + surprise %. Analyst upgrades flow to Ratings + Calendar. Form 4 buys, 13D stakes, shelf pricings tagged to issuer.
Every catalyst, in context.
Beats and misses land with surprise % and YoY deltas already on the card. Analyst upgrades and downgrades feed the Ratings page and its dedicated calendar. Form 4 insider buys, 13D activist stakes, shelf pricings — categorized, tagged, on a per-ticker timeline.
- Earnings with consensus + actual + surprise %
- Per-ticker watchlist with instant alerts
- Ratings calendar with rationale + price target
- Form 4 / 13D filings tagged to the issuer
- NVDA
Beats Q1 by $0.42; revenue guidance raised to $44.0–45.0B (above $42.8B consensus)
Data center revenue up 78% YoY; Blackwell ramp ahead of plan; CFO calls supply constraint resolved by Q3.
EARNINGSGUIDANCE12s ago - PFE
Acquires Acme Therapeutics for $3.4B; $46/share cash, expected close Q3 2026
Adds late-stage oncology pipeline; CEO expects accretion in 2027. Deal subject to shareholder vote.
M&A1m ago - TSLA
Downgraded to Sell at Wells Fargo; price target cut to $120 from $180
Cites margin pressure from China price competition and slower-than-expected energy storage ramp.
ANALYST4m ago - META
Authorizes additional $50B share buyback; expands existing $30B program
Reiterates capex guidance of $94–98B for 2026; AI infrastructure spend tracking to plan.
CAPITAL11m ago
Ask anything. Get a sourced answer.
A research assistant built on GLAZ's own data — SEC filings, real-time wires, 13F holdings, insider trades, analyst actions. It reads the primary sources and answers in seconds, with every figure stamped to its source and date. When the data isn't there, it tells you — it never guesses.
- Grounded in filings — every number traceable, never invented
- Smart money built in — who is buying, selling, upgrading
- Real-time — answers from data seconds old, not a training cutoff
- Knows your portfolio — scan your holdings in a single question
Through Q1 2026 13F filings:
- 6 of 14 tracked funds trimmed CLSK last quarter — two exited the position entirely
- No activist (13D) stake on file
- The CFO sold $1.8M of stock in April; no insider buying in 90 days
- No analyst rating changes since the last earnings miss
Sourced from SEC 13F · Form 4 · analyst actions — with as-of dates
One plan. Everything included.
Annual saves you two months. Either way, 14 days free — $0 today, charged after the trial unless you cancel.
- Real-time feed across 100+ primary-source feeds
- AI-summarized headlines + ticker tags
- Earnings calendar with surprise + YoY
- Watchlist + per-ticker alerts
- Ratings page + analyst-action calendar
$0 today · Card on file required · Cancel anytime before charge
Start trading with the edge.
Fourteen days of full access. $0 today — charged after 14 days unless you cancel. See your first signal within seconds.
Start free trial →